Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.
For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).
Se habla español.
A Study for Adults With Recurrent Ependymoma
National Cancer Institute (NCI) researchers are conducting a study of patients with ependymoma. Ependymomas are rare cancerous tumors that grow in the central nervous system. This study will test if the drug marizomib slows or stops the spread of cancer cells in the brain or spine. Results from this research study may help doctors to control these tumor types.
What the study involves:
- Physical and neurological examination
- EKG to evaluate the heart
- Patient questionnaire about health and symptoms
- MRIs and neurological function tests
- Study of tumor tissue from prior surgeries
- Your samples used for a health evaluation
- Receive drug marizomib for up to 24 cycles. Each cycle is four weeks.
You can participate if you:
- Are age 18 or older
- Are diagnosed with an ependymoma that has returned
- Have been treated with standard therapies
- Are not pregnant or breastfeeding
You can participate in this study by visiting the NIH for a clinical assessment.
The NIH Clinical Center, America's Research Hospital is located on the Metro red line (Medical Center stop) in Bethesda, Maryland.
For more information:
NIH Clinical Center
Office of Patient Recruitment
800-411-1222 (refer to study 19-C-0011)
800-877-8339 TTY / ASCII
Se habla español
Or go online:
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 03/24/2020